ストックスクリーナーアプリを入手
5.41
5.25%
0.27
前日終値:
$5.14
開ける：
$5.25
24時間の取引高:
63,040
Relative Volume:
0.37
時価総額：
$104.53M
収益：
-
当期純損益:
$-22.38M
株価収益率:
-3.4903
EPS:
-1.55
ネットキャッシュフロー:
$-15.54M
1週間 パフォーマンス:
+16.34%
1か月 パフォーマンス:
+7.34%
6か月 パフォーマンス:
-14.53%
1年 パフォーマンス:
-35.13%
1日の値動き範囲:
$5.15
$5.61
1週間の範囲:
$4.55
$5.61
52週間の値動き範囲:
$4.44
$12.10
Nuvectis Pharma Inc Stock (NVCT) Company Profile
名前
Nuvectis Pharma Inc
セクター
電話
360-837-7232
住所
1 BRIDGE PLAZA, SUITE 275, FORT LEE
NVCT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
5.41 | 104.53M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
402.70 | 103.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
712.33 | 78.28B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
615.00 | 36.77B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.31 | 30.35B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.95 | 27.32B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-07-13 | 開始されました | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc (NVCT) 最新ニュース
(NVCT) Long Term Investment Analysis - Stock Traders Daily
Great week for Nuvectis Pharma, Inc. (NASDAQ:NVCT) insiders who have 63% stake and they haven’t stopped buying - Simply Wall St
Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur Acquires 4,500 Shares - MarketBeat
Nuvectis Pharma CEO Ron Bentsur buys $20,925 in shares By Investing.com - Investing.com Australia
Nuvectis Pharma CEO Ron Bentsur buys $20,925 in shares - Investing.com
Nuvectis Pharma stock hits 52-week low at $4.44 amid market challenges - Investing.com Australia
Marlio Charles Mosseri Purchases 17,000 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock - MarketBeat
Nuvectis pharma investor Mosseri-Marlio purchases $79,900 in shares By Investing.com - Investing.com
Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium - The Manila Times
NVCT Stock Hits 52-Week Low at $4.61 Amid Market Challenges - Investing.com
Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know - MSN
Nuvectis Pharma (NVCT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - MSN
Nuvectis Pharma stock hits 52-week low at $4.7 amid market challenges - Investing.com Australia
Nuvectis Pharma stock hits 52-week low at $4.7 amid market challenges By Investing.com - Investing.com South Africa
Nuvectis sinks after early-stage data for ovarian cancer therapy - MSN
Nuvectis pharma officer Enrique Poradosu buys $9,980 in stock By Investing.com - Investing.com Australia
Ron Bentsur Buys Handful Of Shares In Nuvectis Pharma - Simply Wall St
Insider Buying: Nuvectis Pharma Inc (NVCT) Chairman & CEO Acquires Shares - GuruFocus.com
Nuvectis pharma officer Enrique Poradosu buys $9,980 in stock - Investing.com
Vitalli ends work on Daewoong asset; Alector’s $50M loan - Endpoints News
Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur Buys 20,000 Shares - MarketBeat
Nuvectis pharma chairman buys $98,400 in common stock By Investing.com - Investing.com Canada
Nuvectis pharma chairman buys $98,400 in common stock - Investing.com
Nuvectis Pharma reports data from Phase 1b study of NXP800 - Yahoo Finance
Market Alert: Nuvectis Pharma reports promising data for NXP800 in Phase 1b; Advancing Towards Higher Dose Cohort - The Globe and Mail
500: Something went wrong - Investing.com Canada
Why Is Nuvectis Pharma Stock Trading Lower On Thursday?Nuvectis Pharma (NASDAQ:NVCT) - Benzinga
NVCT stock touches 52-week low at $5.05 amid market fluctuations - Investing.com India
U.S. Stock market: Nuvectis Pharma declined by 40.58% while Sow Good was down by 55.30% during mid day trading - Business Upturn
Nuvectis stock sinks on data for cancer drug (NVCT:NASDAQ) - Seeking Alpha
Nuvectis Pharma Stock Plummets on Updated Data for Ovarian Cancer Study - MarketWatch
Nuvectis Pharma Inc trading resumes - TipRanks
U.S. Stock market: Nuvectis Pharma saw a sharp decline of 53.89% while AgEagle Aerial Systems surged by 133.74% in early trading - Business Upturn
Nuvectis Pharma Reports Encouraging NXP800 Interim Data - GlobeNewswire
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase - The Bakersfield Californian
Nuvectis Pharma's NXP800 Shows Promise in Phase 1b Cancer Trial, New Dosing Success | NVCT Stock News - StockTitan
Trading (NVCT) With Integrated Risk Controls - Stock Traders Daily
Nuvectis Pharma (NASDAQ:NVCT) Announces Third Quarter 2024 Financial Results and Business Updates - Defense World
Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
Nuvectis Pharma's VP Michael Carson sells $22.5k in stock - Investing.com
Nuvectis Pharma's VP Michael Carson sells $22.5k in stock By Investing.com - Investing.com UK
FY2024 EPS Estimates for Nuvectis Pharma Raised by Analyst - Defense World
FY2024 EPS Estimate for Nuvectis Pharma Increased by Analyst - MarketBeat
Nuvectis Pharma Inc (NVCT) 財務データ
収益
当期純利益
現金流量
EPS
Nuvectis Pharma Inc (NVCT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mosseri Marlio Charles | 10% Owner |
Dec 13 '24 |
Buy |
4.70 |
17,000 |
79,900 |
2,612,000 |
| Poradosu Enrique | Chief Science & Business Off |
Nov 19 '24 |
Buy |
4.99 |
2,000 |
9,980 |
1,506,319 |
| BENTSUR RON | Chairman & CEO |
Nov 15 '24 |
Buy |
4.92 |
20,000 |
98,400 |
3,266,424 |
| Carson Michael J. | Vice President, Finance |
Nov 07 '24 |
Sale |
8.16 |
2,755 |
22,478 |
87,918 |
| BENTSUR RON | Chairman & CEO |
May 14 '24 |
Buy |
6.74 |
1,940 |
13,076 |
3,246,424 |
| BENTSUR RON | Chairman & CEO |
May 10 '24 |
Buy |
6.40 |
2,000 |
12,800 |
3,244,484 |
| Poradosu Enrique | Chief Science & Business Off |
May 10 '24 |
Buy |
6.29 |
500 |
3,145 |
1,504,319 |
| Shemesh Shay | Chief Dev. & Ops. Officer |
May 10 '24 |
Buy |
6.32 |
1,113 |
7,034 |
1,493,068 |
| BENTSUR RON | Chairman & CEO |
Mar 18 '24 |
Buy |
10.29 |
5,000 |
51,450 |
3,242,484 |
0.48%
1.34%
大文字化:
|
ボリューム (24 時間):